Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 10/20 | 0.45 |
| ▸ | NQO1 | P15559 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751147 | 1.00 | FFAR1 (0.54) | FFAR1GRM5ACACBNQO1KDM4E | |
| SCHEMBL27997120 | 0.79 | ACACB (0.41) | FFAR1ACACBNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL14975683 | 0.79 | FFAR1 (0.60) | FFAR1GRM5KDM4ESMN1; SMN2HPGD | |
| SCHEMBL18342015 | 0.78 | FFAR1 (0.56) | FFAR1GRM5NPC1RAB9A | |
| SCHEMBL31160399 | 0.76 | NQO1 (0.74) | ACACBNQO1LTA4H | |
| SCHEMBL18188367 | 0.74 | GRM5 (0.49) | FFAR1GRM5KDM4ESMN1; SMN2HPGD | |
| SCHEMBL29984617 | 0.73 | ALDH1A1 (0.59) | FFAR1ACACBNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL23666286 | 0.73 | LTA4H (0.63) | FFAR1ACACBNQO1KDM4ESMN1; SMN2 | |
| SCHEMBL9152764 | 0.71 | ACACB (0.50) | FFAR1ACACBNQO1 | |
| SCHEMBL18188087 | 0.71 | GRM5 (0.53) | FFAR1GRM5SMN1; SMN2HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116923-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | SEABELIFE (FR) | 2024-04-11 | — | — | US | disclosed |
| CN-117529317-A | Use of indole, 6-and 7-azaindole derivatives as inhibitors of iron death-mediated cell death | 海洋生命公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4281070-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | Seabelife (FR) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022157392-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | SEABELIFE (FR) | 2022-07-28 | — | — | WO | disclosed |
| EP-3362450-B1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CELLULAR NECROPTOSIS | INST NAT SANTE RECH MED (FR) | 2020-07-01 | — | — | EP | disclosed |
| EP-3362450-B1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CELLULAR NECROPTOSIS | INST NAT SANTE RECH MED (FR) | 2020-07-01 | — | — | EP | disclosed |
| US-10457678-B2 | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-10-29 | — | — | US | disclosed |
| US-10457678-B2 | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-10-29 | — | — | US | disclosed |
| US-20180312502-A1 | N1-And N7-Substituted Sibiriline Derivatives And Their Use As Inhibitor Of Cellular Necroptosis | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-11-01 | — | — | US | disclosed |
| EP-3362450-A1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITOR OF CELLULAR NECROPTOSIS | Institut National de la Sante et de la Recherche Medicale (INSERM) (FR) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017064216-A1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITOR OF CELLULAR NECROPTOSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017064216-A1 | N1- AND N7-SUBSTITUTED SIBIRILINE DERIVATIVES AND THEIR USE AS INHIBITOR OF CELLULAR NECROPTOSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116923-A1 | USE OF INDOLE, 6- AND 7-AZAINDOLE DERIVATIVES AS INHIBITORS OF FERROPTOSIS REGULATED CELL DEATH | AIFM2, SLC40A1, FECH | FFAR1 1313/4885GRM5 858/4885ACACB 3513/4885 |
| US-10457678-B2 | Substituted pyrrolo[2,3-b]pyridines as inhibitors of cellular necroptosis | CASP7, PARK7, RIPK3 | FFAR1 3239/4885GRM5 2644/4885ACACB 4504/4885 |
| US-20180312502-A1 | N1-And N7-Substituted Sibiriline Derivatives And Their Use As Inhibitor Of Cellular Necroptosis | CASP7, RIPK3, PARK7 | FFAR1 2320/4885GRM5 3040/4885ACACB 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.